Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan - Yokota, Shumpei; Itoh, Yasuhiko; Morio, Tomohiro; Origasa, Hideki; Sumitomo, Naokata; Tomobe, Minako; Tanaka, Kunihiko; Minota, Seiji (Annals of the rheumatic diseases, 2016)
Keywords: Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antirheumatic Agents - adverse effects; Antirheumatic Agents - therapeutic use; Arthritis, Juvenile - drug therapy; Child; Clinical and Epidemiological Research; Clinical trials; Disease; Female; Fever; Follow-Up Studies; Humans; Japan; Male; Patients; Pharmaceutical industry; Product Surveillance, Postmarketing; Registries; Surveillance; Time Factors; Treatment Outcome; Japan; DMARDs (biologic); Treatment; Juvenile Idiopathic Arthritis